Immatics US, Inc.
Quick facts
Phase 3 pipeline
- IMA203 · Oncology
IMA203 is a T-cell engager that redirects patient T cells to recognize and kill cancer cells expressing the PRAME antigen. - nivolumab plus relatlimab · Oncology
Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses. - paclitaxel plus carboplatin · Oncology
Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells.
Phase 1 pipeline
- IMA101 product
- IMA201 Product
- IMA202 Product
- IMA203 Product
- IMA203 product- flat dose
- IMA203CD8 Product
- mRNA-4203
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Immatics US, Inc.
What is Immatics US, Inc.'s pipeline?
Immatics US, Inc. has 3 drugs in Phase 3, 0 in Phase 2, 7 in Phase 1. Late-stage candidates include IMA203, nivolumab plus relatlimab, paclitaxel plus carboplatin.
Related
- Sector hub: All tracked pharma companies